Indian Pharma Market Sees A Sharp Spike In Growth In March Led by Covid-19 Drugs: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Indian Pharma Market grew 10.3% YoY in March 2021 versus 1.1% in February 2021 and 8.9% in March 2020.
Vitamins-minerals-nutrients/gastro/pain therapies exhibited a growth of 22.2%/21.6%/14.6% YoY.
Anti-Infectives therapy recovered, with 8.5% YoY growth compared to an 11% decline in February 2021.
Strong growth in these therapies is partly on account of higher offtake of Covid-19 related medicines on a YoY basis.
Respiratory sales are on a downtrend, with a 15.1% YoY decline in March-21 as well.
On a moving annual turnover basis, IPM growth stood at 2.1% YoY.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.